Related Experiment Video

Updated: Jun 23, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis

R T Silver, K Vandris

    Leukemia
    |May 15, 2009
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
    04:36

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

    Published on: October 17, 2025

    Related Experiment Videos

    Last Updated: Jun 23, 2026

    Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
    08:26

    Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

    Published on: June 14, 2018

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
    04:36

    Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

    Published on: October 17, 2025

    Related Concept Videos

    Inhibitors of Viral Protein Synthesis01:30

    Inhibitors of Viral Protein Synthesis

    Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

    Articles linked to this work by shared authors, journal, and citation graph.

    European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

    Leukemia·2020

    A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

    Leukemia·2017

    Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.

    Leukemia·2016

    Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging.

    Journal of thrombosis and haemostasis : JTH·2014

    Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).

    Leukemia·2014

    Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.

    Blood cancer journal·2013

    Mitochondria transfer via tunneling nanotubes drives macrophage immunosuppression and metabolic reprogramming in pediatric AML.

    Leukemia·2026

    Bone health in myelodysplastic neoplasms: results from the prospective longitudinal BoHemE study.

    Leukemia·2026

    RUNX1 aberrations in blast-phase chronic myeloid leukaemia induce the RNA-binding protein SPATS2L, which promotes growth, survival and stress granule assembly.

    Leukemia·2026

    Predicting the clinical course of advanced systemic mastocytosis on treatment with avapritinib or midostaurin.

    Leukemia·2026

    Novel RNA polymerase I and cyclin-dependent kinase combination therapy for the treatment of aggressive acute myeloid leukemia.

    Leukemia·2026

    Measurable residual disease assessment as an early end point of treatment efficacy in acute myeloid leukemia: a multinational PETHEMA study of 2623 patients treated with intensive therapy.

    Leukemia·2026

    Cytomegalovirus Infections Following Pediatric Hematopoietic Stem Cell Transplantation: An 18-Year Single-Center Experience.

    Transplant infectious disease : an official journal of the Transplantation Society·2026

    Complete radiological and biochemical remission at 26 months in a young adult with primary mediastinal yolk sac tumor: a case report and literature review on multimodal management.

    Journal of medical case reports·2026

    Making space for cures: Conditioning for autologous hematopoietic stem cell gene therapies.

    Seminars in hematology·2026

    Charge Comparison of Standalone Middle Meningeal Artery Embolization to Non-surgical Medical Management for Chronic Subdural Hematoma - A Propensity Score Matched Analysis.

    World neurosurgery·2026

    Real-World Outcomes of PRESERFLO MicroShunt Implantations With and Without Adjunctive Healaflow® Application in Glaucoma Patients: A Single-Center Experience.

    Klinische Monatsblatter fur Augenheilkunde·2026

    Generation of a human induced pluripotent stem cell line (ZZUNEUi040-A) from a male patient with hypertrophic cardiomyopathy carrying a heterozygous TPM1 (c.644C > T) mutation.

    Stem cell research·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us